gastric cancer
Conditions
Interventions
Case series:Apatinib mesylate combined with tegafur
Sponsors
Baotou Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 30 patients with advanced ovarian cancer diagnosed by pathology in our hospital from December 2017 to December 2018, aged over 18 years.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women; 2. Participated in other drug clinical trials within 4 weeks before the start of the study. 3. Symptomatic brain/meningeal metastases and simple bone metastases; 4. Patients with hypertension who could not be well controlled by single antihypertensive drugs (systolic pressure > 140 mmHg, diastolic pressure > 90 mmHg), myocardial ischemia or myocardial infarction above grade I, arrhythmia above grade I (including QT interval > 440 ms) or cardiac insufficiency; 5. There are many factors affecting the oral and absorption of drugs (such as inability to swallow, Post-gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.); 6. The coagulation function is abnormal and is undergoing thrombolysis or anticoagulation therapy, which is prone to bleeding; 7. There are clear concerns about gastrointestinal bleeding (e.g. local active ulcer lesions, positive stool occult blood); 8. Arteriovenous thrombosis events occurred within 6 months before the start of the study, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis and pulmonary embolism; 9. Wounds or fractures in the chest and other parts that have not been healed for a long time; 10. Urinary routine indicated that urinary protein (++) and confirmed 24-hour urinary protein quantification > 1.0 G. 11. Severe or uncontrolled infections exist; 12. Mental illness or other conditions affecting patient compliance; 13. Patients with past and present objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc. Other malignant tumors have been reported in the past five years, except for cured basal cell carcinoma of skin and carcinoma in situ of cervix.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;ORR;DCR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety;OS; | — |
Countries
China
Contacts
Public ContactHua Yunqi
Baotou Cancer Hospital
Outcome results
None listed